The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Molecular Cancer Therapeutics

• Publication date

  2015-01-14

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1535-7163.MCT-14-0881-TPMID 25589493
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Preclinical Profile of the HER2-Targeting ADC SYD983/SYD985: Introduction of a New Duocarmycin-Based Linker-Drug Platform

  2014cited by this paper
• Cathepsin B: Multiple roles in cancer

  2014cited by this paper
• Antibody-drug conjugates: an emerging concept in cancer therapy.

  2014cited by this paper
• Preclinical safety profile of trastuzumab emtansine (T-DM1): mechanism of action of its cytotoxic component retained with improved tolerability.

  2013cited by this paper
• Acid-mediated tumor proteolysis: contribution of cysteine cathepsins.

  2013cited by this paper
• Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.

  2013cited by this paper
• Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy

  2013cited by this paper
• What is the European Medicines Agency?

  2012cited by this paper
• Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.

  2012cited by this paper
• Reporting of adjuvant breast cancer trials: when is the right time?

  2012cited by this paper
• Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation.

  2012cited by this paper
• Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.

  2012influential reference
• Trastuzumab emtansine for HER2-positive advanced breast cancer.

  2012cited by this paper
• A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.

  2012cited by this paper
• Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.

  2011cited by this paper
• Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo

  2011cited by this paper
• Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage.

  2011cited by this paper
• Trastuzumab emtansine (T-DM1): a novel agent for targeting HER2+ breast cancer.

  2011cited by this paper
• Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer

  2011cited by this paper
• Production of ES1 plasma carboxylesterase knockout mice for toxicity studies.

  2011cited by this paper
• Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice

  2010cited by this paper
• Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib

  2010cited by this paper
• Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection.

  2009cited by this paper
• New cc-1065 analogs and their conjugates

  2009cited by this paper
• Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate.

  2008cited by this paper
• Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen.

  2006cited by this paper
• Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma.

  2005cited by this paper
• Diagnostic Evaluation of HER-2 as a Molecular Target: An Assessment of Accuracy and Reproducibility of Laboratory Testing in Large, Prospective, Randomized Clinical Trials

  2005cited by this paper
• HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues.

  2004cited by this paper
• Development of potent monoclonal antibody auristatin conjugates for cancer therapy

  2003cited by this paper
• Pericellular pH affects distribution and secretion of cathepsin B in malignant cells.

  1994cited by this paper
• Immunoconjugates containing novel maytansinoids: promising anticancer drugs.

  1992cited by this paper
• Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

  1989cited by this paper
• Antimitotic activity of the potent tumor inhibitor maytansine.

  1975cited by this paper

• Identification of antibody-drug conjugate payloads that are substrates of ATP-binding cassette drug efflux transporters

  2026cites this paper
• Innovations in HER2-targeted therapy: A comprehensive review of trastuzumab deruxtecan.

  2026cites this paper
• Advances in Immunotherapy for HER2 Low-Expressing Triple-Negative Breast Cancer

  2025cites this paper
• Clinical characteristics and therapeutic direction of HER2 low-expression breast cancer

  2025cites this paper
• Toxicities and management strategies of emerging antibody–drug conjugates in breast cancer

  2025cites this paper
• Broadening the Therapeutic Window of ADCs Using Site-Specific Bioconjugation Showcased by an MMAE-Containing Peptide Linker in a CD79b-Targeting ADC

  2025cites this paper
• Comparison of Clinicopathological Characteristics for HER2-Null, HER2-Ultralow and HER2-Low Breast Cancer: A Single-Center Study

  2025cites this paper
• Drug discovery in advanced and recurrent endometrial cancer: Recent advances

  2025cites this paper
• Personalized Treatment in Ovarian Cancer: A Review of Disease Monitoring, Biomarker Expression, and Targeted Treatments for Advanced, Recurrent Ovarian Cancers

  2025cites this paper
• The Site-specific Conjugation Strategy of HER2-targeted Antibody-drug Conjugates and its Application in Tumor Treatment

  2025influential citation
• Clinical and genomic characteristics of HER2-ultralow breast cancer and implications for T-DXd therapy

  2025cites this paper
• Advances in Targeting HER2 across Cancer Subtypes - A Pan-tumor Approach.

  2025cites this paper
• Development and validation of a radiomics-based nomogram for predicting two subtypes of HER2-negative breast cancer

  2024cites this paper
• Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2–Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP)

  2024cites this paper
• Opportunities and Challenges in the Development of Antibody-Drug Conjugate for Triple-Negative Breast Cancer: The Diverse Choices and Changing Needs

  2024cites this paper
• Clinical translation of antibody drug conjugate dosing in solid tumors from preclinical mouse data

  2024cites this paper
• Neoadjuvant chemotherapy efficacy and prognosis in HER2-low and HER2-zero breast cancer patients by HR status: a retrospective study in China

  2024cites this paper
• [Treatment-related adverse events associated with antibody drug conjugate in breast cancer].

  2024cites this paper
• Trastuzumab deruxtecan in breast cancer.

  2024cites this paper
• Implementation of antibody-drug conjugates in HER2-positive solid cancers: Recent advances and future directions.

  2024cites this paper
• Drug conjugates for the treatment of lung cancer: from drug discovery to clinical practice

  2024cites this paper
• Quantitative systems pharmacology modeling of HER2-positive metastatic breast cancer for translational efficacy evaluation and combination assessment across therapeutic modalities

  2024influential citation
• Antibody–drug conjugates transform the outcome of individuals with low‐HER2‐expression advanced breast cancer

  2024cites this paper
• Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives

  2024cites this paper
• Do HER2-Low Tumors Have a Distinct Clinicopathologic Phenotype?

  2023influential citation
• Biology and Treatment of HER2-Low Breast Cancer.

  2023cites this paper
• Antibody–Drug Conjugates (ADC) in HER2/neu-Positive Gynecologic Tumors

  2023cites this paper
• Research Progress and Future Prospect of HER-2 Low Expression Breast Cancer

  2023cites this paper
• The History and Development of HER2 Inhibitors

  2023cites this paper
• Towards a platform quantitative systems pharmacology (QSP) model for preclinical to clinical translation of antibody drug conjugates (ADCs)

  2023cites this paper
• Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression.

  2023cites this paper
• A review of treatment options in HER2‐low breast cancer and proposed treatment sequencing algorithm

  2023cites this paper
• The trichotomy of HER2 expression confers new insights into the understanding and managing for breast cancer stratified by HER2 status

  2023cites this paper
• HER2 in uterine serous carcinoma: Current state and clinical perspectives.

  2023cites this paper
• Analysis of clinical features, genomic landscapes and survival outcomes in HER2-low breast cancer

  2023cites this paper
• HER2 Low Breast Cancer: A New Subtype or a Trojan for Cytotoxic Drug Delivery?

  2023cites this paper
• Detailed curriculum vitae of HER2-targeted therapy.

  2023cites this paper
• Advances in Targeted Therapy of Breast Cancer with Antibody-Drug Conjugate

  2023cites this paper
• Emerging Targeted Therapies for HER2-Positive Breast Cancer

  2023cites this paper
• Clinical Perspective: Antibody-Drug Conjugates (ADCs) for the Treatment of HER2-Positive Breast Cancer.

  2023cites this paper
• HER2-Positive Metastatic Breast Cancer: Available Treatments and Current Developments

  2023cites this paper
• Distribution, dynamic evolution, and clinical outcomes of patients with advanced breast cancer according to HER2 expression

  2023cites this paper
• The HER2-low revolution in breast oncology: steps forward and emerging challenges

  2023cites this paper
• Innovative Therapeutic Approaches for Patients with HER2-Positive Breast Cancer.

  2023cites this paper
• The change of paradigm in the treatment of HER2-positive breast cancer with the development of new generation antibody-drug conjugates

  2023cites this paper
• Clinical development of antibody-drug conjugates in triple negative breast cancer: can we jump higher?

  2022cites this paper
• Comparison of pyrrolobenzodiazepine dimer bis-imine versus mono-imine: DNA interstrand cross-linking, cytotoxicity, and antibody-drug conjugate efficacy and toxicity.

  2022cites this paper
• Comparison of clinicopathological characteristics and response to neoadjuvant chemotherapy between HER2-low and HER2-zero breast cancer

  2022cites this paper
• Quantitative analysis of drug distribution in heterogeneous tissues using dual‐stacking capillary electrophoresis–mass spectrometry

  2022cites this paper
• Resistance to antibody‐drug conjugates in breast cancer: mechanisms and solutions

  2022cites this paper
• Targeting HER2-positive breast cancer: advances and future directions

  2022cites this paper
• Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody–Drug Conjugates in Breast Cancer

  2022cites this paper
• More than Toxins-Current Prospects in Designing the Next Generation of Antibody Drug Conjugates.

  2022cites this paper
• Prognostic and predictive biomarkers with therapeutic targets in breast cancer: A 2022 update on current developments, evidence, and recommendations

  2022cites this paper
• Tailoring antiHer2 treatment strategies in breast cancer and beyond.

  2022cites this paper
• HER2 Inhibition in Gastric Cancer—Novel Therapeutic Approaches for an Established Target

  2022cites this paper
• Immunotherapy for HER2-Positive Breast Cancer: Clinical Evidence and Future Perspectives

  2022cites this paper
• An Innovative Site-Specific Anti-HER2 Antibody-Drug Conjugate with High Homogeneity and Improved Therapeutic Index

  2022cites this paper
• Clinical significance of HER2-low expression in early breast cancer: a nationwide study from the Korean Breast Cancer Society

  2022cites this paper
• Bystander effect of antibody–drug conjugates: fact or fiction?

  2022cites this paper
• Single Mutation on Trastuzumab Modulates the Stability of Antibody–Drug Conjugates Built Using Acetal-Based Linkers and Thiol-Maleimide Chemistry

  2022cites this paper
• Antibody-Drug Conjugates Targeting the Human Epidermal Growth Factor Receptor Family in Cancers

  2022cites this paper
• A review on recent synthetic routes and computational approaches for antibody drug conjugation developments used in anti-cancer therapy

  2022cites this paper
• Antibody-drug conjugates: Resurgent anticancer agents with multi-targeted therapeutic potential.

  2022cites this paper
• Immunotherapy for Breast Cancer Treatment

  2021cites this paper
• Clinical Development of New Antibody–Drug Conjugates in Breast Cancer: To Infinity and Beyond

  2021cites this paper
• Unlocking the potential of antibody–drug conjugates for cancer therapy

  2021cites this paper
• Antibody–Drug Conjugate Efficacy in Neuroblastoma: Role of Payload, Resistance Mechanisms, Target Density, and Antibody Internalization

  2021cites this paper
• DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo.

  2021cites this paper
• Development and Application of a Single Cell-Level PK-PD Model for ADCs

  2021cites this paper
• Duocarmycin-based antibody-drug conjugates as an emerging biotherapeutic entity for targeted cancer therapy: pharmaceutical strategy and clinical progress.

  2021cites this paper
• Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies

  2021cites this paper
• Clinical Signi cance and Genetic Characteristics in HER2 Low Expression Tumors of Hormone Receptor Positive Breast Cancer Patients

  2021cites this paper
• Antibody drug conjugates for patients with breast cancer.

  2021cites this paper
• Human epidermal growth factor receptor 2 targeted therapy in endometrial cancer: Clinical and pathological perspectives

  2021cites this paper
• Targeting MICA/B with cytotoxic therapeutic antibodies leads to tumor control

  2021cites this paper
• Targeted clearance of senescent cells using an antibody-drug conjugate against a specific membrane marker

  2021cites this paper
• Antibody–Drug Conjugates for the Treatment of Breast Cancer

  2021cites this paper
• Targeting HER2 in breast cancer: new drugs and paradigms on the horizon

  2021cites this paper
• The Exciting New Field of HER2-Low Breast Cancer Treatment

  2021cites this paper
• Mechanistic Modeling of Intra‐Tumor Spatial Distribution of Antibody‐Drug Conjugates: Insights into Dosing Strategies in Oncology

  2020cites this paper
• Considerations for the Design of Antibody-Based Therapeutics.

  2020cites this paper
• Trastuzumab Emtansine: Mechanisms of Action and Resistance, Clinical Progress, and Beyond.

  2020cites this paper
• Clinical development of immunotherapies for HER2+ breast cancer: a review of HER2-directed monoclonal antibodies and beyond

  2020cites this paper
• Crosstalk between HER2 and PD-1/PD-L1 in Breast Cancer: From Clinical Applications to Mathematical Models

  2020cites this paper
• The Second Generation Antibody-Drug Conjugate SYD985 Overcomes Resistances to T-DM1

  2020cites this paper
• Advances in Antibody–Drug Conjugate Design: Current Clinical Landscape and Future Innovations

  2020cites this paper
• Antibody-Drug Conjugates: Patient and Treatment Selection.

  2020cites this paper
• HER2-Low Breast Cancer: Pathological and Clinical Landscape.

  2020cites this paper
• Combination Therapy and Nanoparticulate Systems: Smart Approaches for the Effective Treatment of Breast Cancer

  2020cites this paper
• T-DM1-induced thrombocytopenia in breast cancer patients: New perspectives.

  2020cites this paper
• Mechanistic Quantitative Pharmacology Strategies for the Early Clinical Development of Bispecific Antibodies in Oncology

  2020cites this paper
• Antibody-drug conjugates in breast cancer: the chemotherapy of the future?

  2020cites this paper
• ARX788, a Site-specific Anti-HER2 Antibody–Drug Conjugate, Demonstrates Potent and Selective Activity in HER2-low and T-DM1–resistant Breast and Gastric Cancers

  2020cites this paper
• A platform for the generation of site-specific antibody-drug conjugates that allows for selective reduction of engineered cysteines.

  2020cites this paper
• Antibody–drug conjugates to treat gastric cancer

  2020cites this paper
• The Evolving Landscape of HER2-Directed Breast Cancer Therapy

  2020cites this paper
• How can the potential of the duocarmycins be unlocked for cancer therapy?

  2020cites this paper
• Survival Prolongation Index as a Novel Metric to Assess Anti-Tumor Activity in Xenograft Models

  2019cites this paper
• Antibody-Drug Conjugates Targeting the Urokinase Receptor (uPAR) as a Possible Treatment of Aggressive Breast Cancer

  2019cites this paper